Morgan Stanley Exagen Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Exagen Inc. stock. As of the latest transaction made, Morgan Stanley holds 482,420 shares of XGN stock, worth $878,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares

482,420

Previous 483,920 0.31%

Holding current value

$878,004

Previous $963,000 20.35%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.42 - $2.3 $2,130 - $3,449	-1,500 Reduced 0.31%	482,420 $767,000
Q4 2023 Feb 13, 2024	BUY	$1.45 - $2.39 $4,234 - $6,978	2,920 Added 0.61%	483,920 $963,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.48 $169 - $250	-72 Reduced 0.01%	481,000 $1.39 Million
Q1 2023 May 15, 2023	SELL	$2.23 - $2.9 $8,627 - $11,220	-3,869 Reduced 0.8%	481,072 $1.17 Million
Q4 2022 Feb 14, 2023	SELL	$2.1 - $3.4 $18,280 - $29,597	-8,705 Reduced 1.76%	484,941 $1.16 Million

Q3 2022 Nov 14, 2022	SELL	$3.43 - $8.68 $17,904 - $45,309	-5,220 Reduced 1.05%	493,646 $1.34 Million
Q2 2022 Oct 27, 2022	SELL	$4.18 - $7.74 $149,246 - $276,356	-35,705 Reduced 6.68%	498,866 $2.86 Million
Q2 2022 Aug 15, 2022	SELL	$4.18 - $7.74 $149,246 - $276,356	-35,705 Reduced 6.68%	498,866 $2.86 Million
Q1 2022 Oct 27, 2022	BUY	$7.12 - $11.06 $254,219 - $394,897	35,705 Added 7.16%	534,571 $4.29 Million
Q1 2022 May 13, 2022	BUY	$7.12 - $11.06 $74,368 - $115,521	10,445 Added 1.99%	534,571 $4.29 Million
Q4 2021 Feb 14, 2022	BUY	$8.97 - $14.08 $229,084 - $359,589	25,539 Added 5.12%	524,126 $6.1 Million
Q3 2021 Nov 15, 2021	BUY	$10.25 - $15.21 $5.11 Million - $7.58 Million	498,587 New	498,587 $6.78 Million

Others Institutions Holding XGN

# of Institutions

Shares Held

6.21M

Call Options Held

1.6K

Put Options Held

4.1K

View Full List

About EXAGEN INC.

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $29.6M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

More about XGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account